Familial Chylomicronemia Syndrome (FCS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder caused by mutations in lipoprotein lipase. The mutations result in the accumulation of chylomicrons in plasma and hypertriglyceridemia. Elevated triglyceride levels further cause several complications, such as acute pancreatitis. FCS has been called different names. Some commonly used synonyms for FCS include Lipoprotein lipase deficiency (LPLD), Type 1 hyperlipoproteinemia, and Endogenous hypertriglyceridemia.

·       FCS is diagnosed based on fasting triglyceride levels above or 750 mg/dL (8.5 mmol/L). The diagnosis of FCS can also be confirmed through genetic testing for mutations in the gene that encodes lipoprotein lipase (LPL).

·       Familial Chylomicronemia Syndrome (FCS) is estimated to occur in 1 in 1 to 2 million people as per Thelansis’ research which encompasses both the secondary and primary research findings. FCS affects all ages, gender, races, and ethnicities equally. Incidence of Familial chylomicronemia syndrome can be observed at any age.

Thelansis’s “Familial Chylomicronemia Syndrome (FCS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Familial Chylomicronemia Syndrome (FCS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Familial Chylomicronemia Syndrome (FCS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Familial Chylomicronemia Syndrome (FCS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Familial Chylomicronemia Syndrome (FCS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032